BioVersys AG
BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE
Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in patients with newly diagnosed drug-sensitive…